Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04478305 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Affect of Duavive on Mood & Anxiety Symptoms

Study acronym: DOMA
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 3, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary and study completion dates: Sep 2021 to Dec 2025
    • Start date changed from estimate of Mar 2021 to Jul 3, 2024
    • Study sites: 0 to 1
    • Eligibility criteria shortened, about 12 words
  2. Start date: Sep 2020 to Mar 2021v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.
Trial Details
NCT Number NCT04478305
Lead Sponsor St. Joseph's Healthcare Hamilton
Collaborators: McMaster University, Pfizer
Conditions
(from sponsor)		 Menopause, Depression, Anxiety, Sleep, Menopause Related Conditions
Related terms Anxiety Disorders, Depression
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov